251 Followers on Owler

Mesoblast

is an Australia-based regenerative medicine company that develops allogeneic cellular medicines for the treatment of inflammatory and cardiovascular diseases... Read more
OverviewCompetitorsAcquisitionsFundingNews & Insights

Mesoblast

is an Australia-based regenerative medicine company that develops allogeneic cellular medicines for the treatment of inflammatory and cardiovascular diseases... Read more
Mesoblast Managing Director & CEO: Silviu Itescu

Managing Director & CEO

Silviu Itescu

CEO Approval Rating

90/100

2004

PublicAustralian Securities ExchangeMSB

Pharmaceuticals & Biotechnology
Biotechnology
2836 NAICS listing

Annual Revenue
$5.9M
Employees
73
Funding
$702.4M
Acquisitions
1

News

Conference Presentation
Dec 03, 2025
Benzinga
Mesoblast Participation at Piper Sandler Conference
Product Launch
Sep 15, 2025
Benzinga
Successful Commercial Launch of Ryoncil Highlighted at Global Healthcare Conferences
Funding
Sep 06, 2025
Life Care News
Mesoblast received $50M in Post-IPO Debt Funding

Mesoblast Competitors

1Cynata Therapeutics
2Loam Bio
3Advancell
4Caladrius
5Pluristem
6Sirtex
7BioCardia
8Orgenesis
9Cesca
10Osiris Therapeutics
Unlock 14 + competitors

Trending Companies